Chardan Capital Keeps Their Buy Rating on Vascular Biogenics (VBLT)

By Jason Carr

In a report released today, Geulah Livshits from Chardan Capital reiterated a Buy rating on Vascular Biogenics (VBLTResearch Report), with a price target of $3.25. The company’s shares closed last Monday at $1.15.

According to TipRanks.com, Livshits is a 1-star analyst with an average return of -4.6% and a 26.6% success rate. Livshits covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Rocket Pharmaceuticals, and Crispr Therapeutics AG.

Currently, the analyst consensus on Vascular Biogenics is a Strong Buy with an average price target of $3.00, which is a 185.7% upside from current levels. In a report issued on March 19, Oppenheimer also maintained a Buy rating on the stock with a $2.00 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $1.71 and a one-year low of $0.90. Currently, Vascular Biogenics has an average volume of 97.56K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi’in, Israel.